KM Research Hub

REVIEW LEDGER

论文复核台

集中查看元数据入排不确定项,以及已识别 KM 但需确认 No. at risk 的内容复核项。

论文元数据入排图像/No. at risk 复核依据
A phase 3 trial of GB-K02 pegfilgrastim biosimilar for preventing chemotherapy-induced neutropenia in breast cancer.PMID 42894857 · 2026-Nov-20needs_review未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。pending-未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。
BEAT-SC: randomized, controlled, double-blind phase III study of bevacizumab plus atezolizumab and chemotherapy as first-line treatment of extensive-stage small cell lung cancer.PMID 43064397 · 2026-Nov-20needs_review未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。pending-未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。
Efficacy and safety of adjunctive use of rifaximin in preventing radiotherapy-induced diarrhea in cancer patients: a randomized controlled trial.PMID 43052387 · 2026-Nov-19needs_review未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。pending-未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。
Comparative Evaluation of Topical Placental Extract versus Povidone-Iodine Dressing in the Management of Chronic Nonhealing Ulcers: A Prospective Randomized Controlled Trial.PMID 43049108 · 2026-Nov-18needs_review未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。pending-未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。
Protocol of the randomized controlled trial of electronic Patient-Reported Outcome Monitoring with Integrated hospital-community pharmaciSt Engagement for diverse outpatient anticancer chemotherapy: the PRO-MISE trial.PMID 43050069 · 2026-Nov-18needs_review未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。pending-未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。
A pilot randomized controlled trial of the feasibility and safety of a combined Epigallocatechin-3-gallate (EGCG) and vitamin C nutraceutical in pre-frail and frail older cancer survivors: Results from the ReFOCUS1 trial.PMID 43050827 · 2026-Nov-18needs_review未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。pending-未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。
Five-Year Survival After Perioperative Nutritional Supplementation in Gastrointestinal Cancer Surgery: Follow-Up of the PROGRESS Feasibility Trial.PMID 43050999 · 2026-Nov-18needs_review未在 PubMed 元数据中确认 Phase III/IIIb 或 Phase II/III 证据,需复核正式试验阶段。pending-未在 PubMed 元数据中确认 Phase III/IIIb 或 Phase II/III 证据,需复核正式试验阶段。
A randomized trial to evaluate the effect of epigallocatechin gallate (EGCG) on EBV reactivation in patients with nasopharyngeal carcinoma in remission -the TCOG T2312 study.PMID 42833136 · 2026-Nov-17needs_review未在 PubMed 元数据中确认 Phase III/IIIb 或 Phase II/III 证据,需复核正式试验阶段。pending-未在 PubMed 元数据中确认 Phase III/IIIb 或 Phase II/III 证据,需复核正式试验阶段。
A Bayesian reanalysis of the THOR trial cohort 1 using reconstructed individual patient data: interval-specific effects and clinically interpretable estimands under non-proportional hazards.PMID 42632050 · 2026-Nov-13needs_review已见 Phase III 和 time-to-event 信号,但随机分配证据不足,需复核。pending-已见 Phase III 和 time-to-event 信号,但随机分配证据不足,需复核。
Self-guided web-based mindfulness and skills-based distress reduction training versus treatment as usual optimised in patients with cancer (Reduct): a multicentre, parallel-group, randomised controlled trial.PMID 43034068 · 2026-Nov-13needs_review未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。pending-未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。
RINGSIDE Phase II Study of Varegacestat for Treatment of Desmoid Tumors: A Randomized Dose-Finding Clinical Trial.PMID 42848980 · 2026-Nov-10needs_review未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。pending-未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。
Zone-specific lymph node metastasis prediction model in clinical stage I-II non-small cell lung cancer: a supplementary analysis of JCOG1413.PMID 43013968 · 2026-Nov-10needs_review未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。pending-未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。
Early oral nutritional supplementation combined with graded functional exercise for postoperative recovery in patients undergoing pancreaticoduodenectomy.PMID 42563597 · 2026-Nov-04needs_review未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。pending-未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。
B cell depletion improves therapeutic index of combination checkpoint blockade in patients with advanced melanoma.PMID 42640721 · 2026-Nov-02needs_review未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。pending-未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。
Stereotactic Ablative Radiotherapy Versus Surgical Resection for Early-Stage Non-Small Cell Lung Cancer: An Emulated Target Trial.PMID 42970669 · 2026-Nov-02needs_review未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。pending-未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。
A Randomized Factorial Trial of Varenicline, Nicotine Lozenges, and Smartphone Medication Adherence Reminders for Smoking Cessation: Protocol for the COMBO II Study.PMID 42970756 · 2026-Nov-02needs_review未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。pending-未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。
Specialist Referral for Cardiovascular Risk in Patients With Prostate Cancer: A Randomized Clinical Trial.PMID 42669035 · 2026-Nov-01needs_review未在 PubMed 元数据中确认 Phase III/IIIb 或 Phase II/III 证据,需复核正式试验阶段。pending-未在 PubMed 元数据中确认 Phase III/IIIb 或 Phase II/III 证据,需复核正式试验阶段。
Multidisciplinary Rehabilitation Following Upper Gastrointestinal Cancer Surgery (RESTORE II): A Definitive Randomized Controlled Trial.PMID 42681576 · 2026-Nov-01needs_review未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。pending-未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。
Impact of Side-to-Side Versus End-to-Side Gastrojejunostomy on the Rate of Delayed Gastric Emptying After Pancreatoduodenectomy (IPAD study): A Randomized Controlled Trial.PMID 42832388 · 2026-Nov-01needs_review未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。pending-未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。
Is early combination therapy associated with lower risk of respiratory failure in severely immunocompromised hosts with COVID-19? a target trial emulation study from the omicron-dominant era.PMID 42593592 · 2026-Novneeds_review未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。pending-未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。
Ultrahypofractionated linac-based radiotherapy of primary prostate cancer - early results of an Austrian nationwide registry study.PMID 42621857 · 2026-Novneeds_review未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。pending-未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。
A randomized pilot trial comparing anti-thymocyte globulin with anti-thymocyte globulin plus post transplant cyclophosphamide for prophylaxis against acute and chronic graft versus host disease in matched donor hematopoietic cell transplants - a study from the Cell Therapy Transplant Canada/ Australasian Leukemia Lymphoma Group Consortium.PMID 42629427 · 2026-Novneeds_review已见 Phase III 随机试验与 time-to-event 终点,但药物干预证据不足,需复核。pending-已见 Phase III 随机试验与 time-to-event 终点,但药物干预证据不足,需复核。
Expert Perspectives on TGCT and the Outcomes of the Phase 3 MANEUVER Study of Pimicotinib Presented at ASCO and ESMO 2025: A Podcast Discussion.PMID 42631796 · 2026-Novneeds_review未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。pending-未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。
Daratumumab, lenalidomide, and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: MAIA final survival analysis.PMID 42637879 · 2026-Novneeds_review未在 PubMed 元数据中确认 Phase III/IIIb 或 Phase II/III 证据,需复核正式试验阶段。pending-未在 PubMed 元数据中确认 Phase III/IIIb 或 Phase II/III 证据,需复核正式试验阶段。
Subtyping limited stage small cell lung cancer (LS SCLC) reveals inflammatory subtypes with improved chemoradiotherapy outcomes.PMID 42691846 · 2026-Novneeds_review未在 PubMed 元数据中确认 Phase III/IIIb 或 Phase II/III 证据,需复核正式试验阶段。pending-未在 PubMed 元数据中确认 Phase III/IIIb 或 Phase II/III 证据,需复核正式试验阶段。
Early adverse events and patient-reported outcomes after salvage radiotherapy following prostatectomy according to fractionation schedule: Interim analysis of the phase III URONCOR 06-24 trial.PMID 42741462 · 2026-Novneeds_review未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。pending-未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。
Tamibarotene with venetoclax and azacitidine in RARA+ acute myeloid leukemia: results from the SY-1425-202 study.PMID 42761251 · 2026-Novneeds_review未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。pending-未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。
Prognostic impact of diabetes or hypertension in smokers with CRPC receiving enzalutamide or abiraterone.PMID 42762423 · 2026-Novneeds_review未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。pending-未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。
Ketamine Versus Magnesium Sulphate as Adjuvants to Bupivacaine in Pectoral Nerve Blocks for Mastectomy: A Randomized, Double-Blind Trial.PMID 42892306 · 2026-Novneeds_review未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。pending-未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。
Effect of two common GVHD prophylaxis regimens on the gut microbiome in a randomized phase 3 trial.PMID 43020901 · 2026-Novneeds_review已见 Phase III 随机试验与 time-to-event 终点,但药物干预证据不足,需复核。pending-已见 Phase III 随机试验与 time-to-event 终点,但药物干预证据不足,需复核。
Efficacy and Safety of ramucirumab Combined With Nab-paclitaxel, Lobaplatin, and S-1 in Conversion Therapy for Unresectable Advanced Gastric Cancer: Preliminary Results of Conversion Therapy Cohort of RNPLS-01 Trial.PMID 42984816 · 2026-Novneeds_review未在 PubMed 元数据中确认 Phase III/IIIb 或 Phase II/III 证据,需复核正式试验阶段。pending-未在 PubMed 元数据中确认 Phase III/IIIb 或 Phase II/III 证据,需复核正式试验阶段。
Personalized biomarker-based treatment strategy in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: Results of the biomarker-driven cohorts of the EORTC-HNCG-1559 trial (UPSTREAM).PMID 42976409 · 2026-Oct-30needs_review未在 PubMed 元数据中确认 Phase III/IIIb 或 Phase II/III 证据,需复核正式试验阶段。pending-未在 PubMed 元数据中确认 Phase III/IIIb 或 Phase II/III 证据,需复核正式试验阶段。
Patient reported swallowing outcomes after prophylactic versus reactive gastrostomy during chemoradiotherapy for head and neck cancer: Results from the SwallPEG randomized trial.PMID 42951256 · 2026-Oct-28needs_review未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。pending-未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。
Real-Time Electronic Patient-Reported Outcome Monitoring With Digital Triage and Care-Team Integration in Early Breast Cancer: ENABLE Randomized Controlled Trial.PMID 42954133 · 2026-Oct-28needs_review未在 PubMed 元数据中确认 Phase III/IIIb 或 Phase II/III 证据,需复核正式试验阶段。pending-未在 PubMed 元数据中确认 Phase III/IIIb 或 Phase II/III 证据,需复核正式试验阶段。
CPS + EG and Neo-Bioscore predict individual outcomes but not trial results after neoadjuvant therapy for early breast cancer.PMID 42945961 · 2026-Oct-27needs_review未在 PubMed 元数据中确认 Phase III/IIIb 或 Phase II/III 证据,需复核正式试验阶段。pending-未在 PubMed 元数据中确认 Phase III/IIIb 或 Phase II/III 证据,需复核正式试验阶段。
Experience of participating in a randomised controlled feasibility trial of surgery versus no surgery as part of multimodality treatment in stage III-N2 non-small cell lung cancer: PIONEER.PMID 42933815 · 2026-Oct-26needs_review未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。pending-未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。
A cluster-randomized trial of the school-based 'Superprotegidas' behavioral intervention to improve HPV vaccination uptake in Colombian girls.PMID 42753387 · 2026-Oct-24needs_review未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。pending-未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。
Entinostat plus exemestane for hormone receptor-positive advanced breast cancer: long-term overall survival results from the EOC103A3101 randomized controlled trial.PMID 42897132 · 2026-Oct-20needs_review未在 PubMed 元数据中确认 Phase III/IIIb 或 Phase II/III 证据,需复核正式试验阶段。pending-未在 PubMed 元数据中确认 Phase III/IIIb 或 Phase II/III 证据,需复核正式试验阶段。
Vibostolimab Coformulated with Pembrolizumab Plus Chemotherapy as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer.PMID 42900351 · 2026-Oct-20needs_review未在 PubMed 元数据中确认 Phase III/IIIb 或 Phase II/III 证据,需复核正式试验阶段。pending-未在 PubMed 元数据中确认 Phase III/IIIb 或 Phase II/III 证据,需复核正式试验阶段。
Comparison of intensity-modulated proton therapy (IMPT) and intensity-modulated radiotherapy (IMRT) for oropharyngeal cancer: efficacy and toxicity differ by outcome measure.PMID 42901049 · 2026-Oct-20needs_review已见 Phase III 随机试验与 time-to-event 终点,但药物干预证据不足,需复核。pending-已见 Phase III 随机试验与 time-to-event 终点,但药物干预证据不足,需复核。
Effects of SMOFlipid-based versus soybean oil-based high-protein parenteral nutrition on hematologic, biochemical, and clinical outcomes after allogeneic hematopoietic stem cell transplantation in children with acute leukemia: a randomized double-blind controlled trial.PMID 43057068 · 2026-Oct-20needs_review未在 PubMed 元数据中确认 Phase III/IIIb 或 Phase II/III 证据,需复核正式试验阶段。pending-未在 PubMed 元数据中确认 Phase III/IIIb 或 Phase II/III 证据,需复核正式试验阶段。
Consolidation With Hyper-CVAD or VP Plus Dasatinib in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Randomized Controlled Trial.PMID 43026087 · 2026-Oct-19needs_review未在 PubMed 元数据中确认 Phase III/IIIb 或 Phase II/III 证据,需复核正式试验阶段。pending-未在 PubMed 元数据中确认 Phase III/IIIb 或 Phase II/III 证据,需复核正式试验阶段。
Assessing the effect of chemotherapy dose reductions and time delay on event-free survival in Ewing Sarcoma: A retrospective analysis of the Euro Ewing 2012 trial.PMID 42766959 · 2026-Oct-16needs_review未在 PubMed 元数据中确认 Phase III/IIIb 或 Phase II/III 证据,需复核正式试验阶段。pending-未在 PubMed 元数据中确认 Phase III/IIIb 或 Phase II/III 证据,需复核正式试验阶段。
[177Lu]Lu-DOTATATE Versus High-Dose Somatostatin Analogues in Advanced Gastroenteropancreatic Neuroendocrine Tumors: Pooled Evidence From 3 Phase 3 Randomized Trials.PMID 42881497 · 2026-Oct-16needs_review未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。pending-未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。
FDA Approval Summary: Erdafitinib for FGFR3-Altered Locally Advanced or Metastatic Urothelial Carcinoma.PMID 42584173 · 2026-Oct-15needs_review未在 PubMed 元数据中确认 Phase III/IIIb 或 Phase II/III 证据,需复核正式试验阶段。pending-未在 PubMed 元数据中确认 Phase III/IIIb 或 Phase II/III 证据,需复核正式试验阶段。
VERIFY: A Phase III Trial of Rusfertide Versus Placebo in Phlebotomy-Dependent Patients With Polycythemia Vera Receiving Standard-of-Care Therapy.PMID 42868322 · 2026-Oct-13needs_review未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。pending-未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。
American Radium Society Appropriate Use Criteria: Accelerated hypofractionated radiotherapy in the multidisciplinary management of locally-advanced non-small cell lung cancer ineligible for concurrent chemotherapy.PMID 42869299 · 2026-Oct-13needs_review未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。pending-未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。
Baseline Tumor Transcriptional Features and Event-Free Survival After Anti-CD19 CAR T-Cell Therapy with Axicabtagene Ciloleucel in Large B-Cell Lymphoma: An Exploratory Reanalysis of the Randomized ZUMA-7 Trial.PMID 42930590 · 2026-Oct-13needs_review未在 PubMed 元数据中确认 Phase III/IIIb 或 Phase II/III 证据,需复核正式试验阶段。pending-未在 PubMed 元数据中确认 Phase III/IIIb 或 Phase II/III 证据,需复核正式试验阶段。
Validation of the International Working Group 2023 response criteria for higher risk myelodysplastic syndromes/neoplasms using the International Consortium for Myelodysplastic Syndromes VALIDATE database and a randomized phase III trial.PMID 42845057 · 2026-Oct-08needs_review已见 Phase III 随机试验与 time-to-event 终点,但药物干预证据不足,需复核。pending-已见 Phase III 随机试验与 time-to-event 终点,但药物干预证据不足,需复核。
Long-term efficacy, clinical outcomes, and safety of vimseltinib in patients with tenosynovial giant cell tumor: results from the MOTION phase 3 trial.PMID 42898002 · 2026-Oct-07needs_review未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。pending-未可靠识别 OS/PFS/DFS/EFS/RFS/TTP、Kaplan-Meier、HR 或其他 time-to-event 结局,需复核。